November 15, 2023 / TORONTO, ON / DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a generative artificial intelligence healthcare company, is pleased to announce it has been accepted into the Southern Ontario Pharmaceutical & Health Innovation Ecosystem (“SOPHIE”) Program to accelerate the clinical and commercialization efforts in Canada for the Company’s CERVAI™ Brain Health AI Platform.
The SOPHIE program supports collaborative projects for Ontario-based life science firms in the later stages of commercialization. DiagnaMed can leverage funding to work directly with an academic or hospital partner in Hamilton’s ecosystem, such as McMaster University, Mohawk College, Hamilton Health Sciences, and St. Joseph’s Health Centre Foundation.
A world first, CERVAI™ consists of a Brain Age™ Estimation and Brain Health Assessment tool. The Brain Age™ Estimation tool includes a novel electroencephalogram headset and machine-learning model. It integrates proprietary software into unified and standardized data recording protocols. The Brain Health Assessment tool generates clinician-observed measures and a brain health score. These combined allow users to be proactive in achieving their brain health goals. Future versions of CERVAI™ will incorporate OpenAI’s GPT platform to develop personalized treatment plans.
DiagnaMed expects the launch of the initial commercial version of CERVAI™ in December 2023 and first sales to occur throughout Q1-2024. CERVAI™ can be available at health centers, doctor offices, hospitals, clinics, pharmacies, and homes. Discussions with clinics and research centers for CERVAI™ in Canada and the U.S. are taking place. DiagnaMed plans to partner with digital health companies for international commercialization.
Fabio Chianelli, Chairman and CEO of DiagnaMed, commented: “We are happy to be accepted into the SOPHIE program to accelerate the clinical and commercialization initiatives of CERVAI™, our novel brain health AI platform. As we near the commercial launch for CERVAI™, we continue leveraging expertise from Canada’s respected life sciences ecosystem to improve CERVAI™’s positioning and global expansion goals.”
The SOPHIE Program is a three-year program funded by the Government of Canada through the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), delivered in partnership with Innovation Factory’s commercialization services and the Synapse Life Science Consortium’s strategic network to leverage access to Hamilton’s unique life sciences capabilities and research expertise.
The CERVAI™ Healthcare Provider Network partnership program is open for enrollment. If interested in joining or learning more, prospective partners are encouraged to visit https://www.diagnamed.com/hcpartner.
About DiagnaMed
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF), a generative artificial intelligence healthcare company, is focused on developing and commercializing CERVAI™, a proprietary brain health AI platform. Learn more at DiagnaMed.com.
For more information about DiagnaMed, please contact:
Fabio Chianelli
Chairman and CEO
DiagnaMed Holdings Corp.
Tel: 416-800-2684
Email: info@diagnamed.com
Website: www.diagnamed.com